Home
Keys to Success in Medicine
Cardiovascular System
Respiratory System
Locomotor System
Endocrine and Metabolic System
Kidneys and Urinary System
Gastrointestinal Tract
Central Nervous System
Haematological System
Integumental System
Reproductive and Genital System
Analysing Medical Investigations
Recommended Reading
Forum
Links

amazon astore

ydr

aces for paces

Clinical Skills Blogspot

Cranial Diabetes Insipidus

Title               

Ñ    Cranial Diabetes Insipidus   

Definition

Ñ    Disorder of the neurohypophysial system

Ñ    Deficiency of anti diuretic hormone (ADH, vasopressin)

Characterised by:

Ñ    Passage of large volumes of dilute urine

Ñ    Excessive thirst

Pathogenesis

Primary

Ñ    Autosomal dominant inheritance

Ñ    DIDMOAD syndrome:

Diabetes insipidus, diabetes mellitus, optic atrophy, deafness

Ñ    Idiopathic:

Often autoimmune

Secondary

Ñ    Trauma:

Head injury, surgery

Ñ    Inflammation:

Meningitis, encephalitis, granulomas, cerebral abscess

Ñ    Neoplasm:

 Pituitary tumours, hypothalamic tumours, secondary deposits, lymphoma, craniopharyngioma

Ñ    Vascular:

Pituitary infarction, pituitary haemorrhage

Pathophysiology

Ñ    Lack of ADH results in failure to reabsorb water in the collecting ducts thus causing polyuria and compensatory polydypsia

Clinical Features

History

Onset

Ñ    Insidious or abrupt

KUS

Ñ    Polyuria

Ñ    Polydypsia

Examination

CVS

Ñ    Hypovolaemia:

If urinary losses are not replaced

Investigations

Fluids

Urine

Ñ    Large volumes:

24 hour urine < 2L excludes need for further investigation

Ñ    Specific gravity:

<1.005

Ñ    Osmolality:

< 200 mOsm/L

Blood

Biochemistry

Ñ    Osmolality:

High or high normal

Ñ    Plasma Sodium:

High or high normal

Ñ    ADH concentration:

Radioimmunoassay of circulating ADH concentration

Physiological studies

Water Deprivation Test

Ñ    Commencement:

Start the test in the morning, check:

·          Body Weight

·          Venous blood:

Osmolality and electrolytes

·          Urine:

Osmolality, specific gravity

Ñ    Do not allow the patient to drink

Ñ    Hourly body weight, urine osmolality or specific gravity, pulse, blood pressure, serum osmolality

Ñ    Stop dehydration if:

·          Orthostatic hypotension, postural tachycardia

·          Loss of 5% of body weight

·          Urinary concentration: 

Does not increase by more than 0.001 specific gravity or 30 mOsm/L osmolality in sequential specimens

Ñ    Inject 2 micrograms of desmopressin or 5 U of aqueous vasopressin s.c. after taking blood for electrolytes and osmolality

Ñ    Terminate Test:

·          One hour later

Collect urine for osmolality and specific gravity

Interpretation

Ñ    Normal Response:

·          Maximum urine osmolality > plasma osmolality:

Urine specific gravity  > 1.020

Urine Osmolality  > 700 mOsm/L

·          Serum osmolality remains within the normal range

Ñ    Cranial Diabetes Insipidus:

·          Unable to concentrate urine osmolality to greater than plasma osmolality

·          Serum osmolality rises above normal

·          Urine osmolality increases > 50 % after vasopressin injection

Ñ    Partial Diabetes Insipidus:

·          Able to concentrate urine to greater than plasma osmolality

·          Urine osmolality rises to > 9% after vasopressin injection

Ñ    Nephrogenic Diabetes Insipidus:

·          Unable to concentrate urine to greater than plasma osmolality

·          No response to vasopressin

Management

Cure

Ñ    Treatment of the cause should either precede or accompany treatment of diabetes insipidus

Control

Drugs

Hormonal Therapy:

Ñ    Desmopressin (DDAVP), synthetic analogue of arginine vasopressin:

·          Intranasal preparations

·          s.c. if intranasal delivery inappropriate :

Upper respiratory tract infection, allergic rhinitis

·          Intravenous:

Acute situations

Ñ    Lypressin (lysine-8-vasopresin):

Nasal spray

Ñ    Vasopressin tannate in oil:

i.m. acts up to 96 hours

Nonhormonal Therapy

Ñ    Diuretics (Thiazides):

Reduces extra-cellular fluid volume and increases proximal tubular reabsorption

Ñ    ADH-releasing drugs:

Chlorpropamide, carbamazepine, clofibrate

Ñ    Prostaglandin inhibitors:

·          Indomethacin:

Probably decreases renal blood flow and glomerular filtration rate

Ñ    Combinations:

May be used

 

 

[ Back ] [ Up ] [ Next ]

[Up]